Introduction
The causative agent of acquired immunodeficiency syndrome (AIDS) is the human immunodeficiency virus (HIV) (for review see Fauci, 1988) . This virus causes immune system dysfunction by infecting and destroying CD4-expressing T4 lymphocytes (for review see Sattentau and Weiss, 1988 ). An initial event in this process is the binding of the viral coat protein, gp120, to the cell surface CD4 antigen. Several compounds developed and used as dyes have shown the ability to inhibit HIV cell binding, HIV replication, or HIV cytotoxicity (Balzarini et al., 1986a (Balzarini et al., , 1986b Baba et al., 1988; Schols et sl., 1989; Schinazi et sl., 1990) . Agents with these properties could be useful in the prevention or treatment of AIDS (for review see DeClercq, 1989) .As dyes are available in great variety and are amenable to chemical modification, it should be possible to determine the structural prerequisites for their anti-HIV activities. With this information dye analogues suitable for use as anti-HIV drugs could be developed. A possible complication in this undertaking is that dyes, both as a class and individually, produce a number of effects which can interfere with productive HIV infection. These include inhibition of HIV-1 reverse transcriptase (R"D (Balzarini et al., 1986b; Schinazi et aI., 1990) , blockade of the CD4 receptor (Balzarini et al., 1986a; Schols et el., 1989) , and production of a barrier between the viral and cell membranes or binding elements (Schols et el., 1990; Weaver et al., 1990) . Perhaps the most desirable process to attempt to inhibit in terms of eventual drug development is gp120/CD4 binding. A drug that inhibited viral binding would prevent infection of cells, so that it could be used both as a treatment and prophylactically. In addition, receptor binding inhibitors tend to be specific in their effects so that drugs with this mechanism of action may have fewer side effects. The purpose of the present study is to evaluate the contribution of gp120/CD4 binding inhibition to the anti-HIV efficacy of dyes.
Results
Dyes structurally related to anthraquinone, aurin, or naphthalene sulphonic acid showed a wide range of potencies as inhibitors of 1251_gp120 binding to CEM cells (Table 1) . These data confirm previous reports that aurin tricarboxylic acid (ATA) and Evans blue (EB) inhibit binding with micromolar potencies, and that aurin and acid fuchsin are inactive (Schols et aI., 1989; Weaver et al., 1990) .Anti-HIV-1 activity, reported as inhibition of viral replication, or of virally-induced cytotoxicity (Balzarini et al., 1986b; Schinazi et al., 1990) , did not generally predict potency of inhibition of gp120/CD4 binding (Table 1) . Several dyes, reported to inhibit viral effects on cells, had no effect on gp120/CD4 binding. The binding and reported anti-HIV-1 potencies did, however, coincide for five ofthe seven dyes for which both types of data were available. These were EB, Direct Yellow 50, ATA, Acid Blue 80, and Acid Blue 40.
The effects of two of these dyes, ATA and EB, on gp120/CD4 binding was examined in more detail in order to elucidate the mode of inhibition. Binding of 1251_gp120 to the CD4 antigen of CEM cells produced complex saturation isotherms and Scatchard plots which were Table 1 . Comparison of the potencies of dyes in inhibiting gp120/CD4 binding, HIV-1 replication or cytotoxicity, and viral reverse transcriptase.
'lA' indicates that the dye was inactive at the highest concentration tested (100 fLM for gp120 binding).
, Inhibition of cytopathogenicity of HIV-1 in ATH8 cells from Balzarini et al. (1986b) . 2 '>' means that clear inhibition, but not 50%, was reached at the concentration shown (the highest tested). 3 Inhibition of cytopathogenicity of HIV-1 in MT4 cells from Baba et al. (1988). suggestive of three binding components, as previously described ( Fig. 1 ; Kozlowski and Watson, 1990) . In the presence of ATA (56 f.1M) or EB (32 f.1M), the gp120 binding isotherm was depressed ( Fig. 1) . Specifically, the amount of binding in each component of the saturation curve was reduced approximately equally in the presence of either dye, but no change was seen in the concentration range over which each component occurred ( Fig. 1 ). Scatchard plots of these data showed that, in the presence of the dyes, the curves were displaced in both dimensions toward the origin. At a high concentration of ATA (150 f.1M) specific gp120 binding was completely eliminated.
It was difficult to clearly visualize the effect of the dyes on the highest affinity binding component (the first component of the saturation isotherm), owing to the small size of this component. The binding assay was, therefore, scaled up by using larger volumes of cells and ligand at the IC50 (fLM) All of the dyes found in this, or previous, studies to inhibit gp120/CD4 binding have also been shown to possess anti-HIV activity when this endpoint has been measured (Balzarini et aI., 1986b , Schols et al., 1989 Weaver et aI., 1990) . In addition, the present results show that there is a good correspondence between inhibition of gp120/CD4 binding and reported antiviral efficacy for 5 of 7 dyes examined in the present study for which anti-HIV activity data were available. Since the remaining 2 dyes were reported to be more potent inhibitors of HIV cytopathogenicity than their binding activities would indicate, it seems likely that a second antiviral activity, such as inhibition of RT, occurring at a lower concentration, pre-empts the effect of binding inhibition. These data suggest that inhibition of gp120/CD4 binding may be the mechanism by which certain dyes produce their anti-HIV effects. However, it is clearly not the anti-Hlv mechanism for all dyes. Thus, in the present study, several dyes reported to block HIV replication or cytotoxicity (Balzarini et aI., 1986b; Baba et al., 1988; Schinazi et aI., 1990 ) did not inhibit gp120/CD4 binding.
In order to gain information on the manner in which dyes inhibit gp120/CD4 binding, the effects of ATA and EB on the binding saturation isotherm were examined. Given the complexity of the gp120 binding saturation curve, it is difficult to quantitate the binding interaction and its alteration in the presence of dyes. Some qualitative observations can, however, be made. In the presence of ATA or EB, the saturation curve exhibits plateaus at the same ligand concentrations as in the absence of dye, but the heights of the plateaus are reduced. Had the binding isotherm been monophasic, this would suggest a decrease in the number of binding sites with no change in their affinity, or non-competitive inhibition. The Scatchard representations of the data, in which all points are displaced toward the origin in the presence of ATA or EB relative to controls, also suggests non-competitive inhibition. There are three commonly occurring mechanisms for non-competitive inhibition of binding. The first is Discussion same concentrations. ATA (15 f.1M) clearly reduced the height of the high affinity component of the saturation isotherm without affecting the concentration range over which it occurred (Fig. 1) .
The inhibition produced by both ATA and EB was reversible. When cells were incubated with ATA (100f.1M), EB (100 f.1M), or the vehicle (as a control) for 30 min (37°C), washed and placed in fresh buffer, and then incubated with ligand for 10-15 min, there was no inhibition of binding by ATA (130 ± 17% of control, n = 5) and only the hint of inhibition (23 ± 10% inhibition relative to control, n = 5) by EB. 0.6 5 0.9 5 0.5 5 0.3 5 10 5 55 irreversible, or only slowly reversible, binding of the inhibitor to the receptor at or near the ligand binding site. Irreversible binding often involves covalent bond formation between the inhibitor and the binding site. The chemical nature of these dyes does not suggest a covalent linkage with the binding site. Furthermore, the present results show that after the cells are incubated in the presence of EB or ATA, the effects of the dyes on binding can be eliminated by washing out the dye before adding the ligand. A second mechanism for non-competitive inhibition is binding of the inhibitor to a site on the receptor other than the ligand recognition site that, when occupied, alters the ability of the receptor to bind the ligand. This type of interaction is seen in the N-methyl-D-aspartate and GABNbenzodiazepine receptor systems (Cooper et al., 1986; Honore, 1989) . Finally, the inhibitor may bind to a site distal from the receptor and alter aspects of receptor functioning, such as cycling, in a way that interferes with ligand binding. For example, binding of the inhibitor may promote receptor internalization, thus reducing the number of cell surface receptors. The present data do not distinguish between the latter two possibilities. The noncompetitive nature of the inhibition of gp120/CD4 binding by dyes may be an asset in terms of clinical potential for two reasons; first, non-competitive inhibition cannot be overcome by raising the ligand concentration and thus, a drug with this type of action would be effective regardless of viral titre; and second, with non-competitive inhibition receptors are rendered unable to bind the ligand. Thus, a complete inhibition of binding, such as is necessary to prevent viral infection, is easier to achieve. Furthermore, depending on the nature of the change produced in the receptor by the inhibitor, loss of receptor function may occur before binding is completely inhibited. In this case total inhibition of binding might not be necessary in order to see anti-HIV effects.
The present results fail to support two mechanisms put forward in the literature by which dyes could inhibit gp120 binding. According to the first of these mechanisms, dyes inhibit gp120 binding by coating or 'shielding' the gp120 (Schols et sl., 1990) . The other mechanism proposes that dyes alter the charge of the cell membrane, thus repelling the viral gp120 0Neaveret al., 1990). Since these mechanisms depend upon general physical properties of gp120, such as its charge, to produce binding inhibition, it might be assumed that the binding of other ligands with similar physical characteristics to their receptors would also be inhibited. Both of these mechanisms would, by virtue of their interference with the binding capability of the ligand, produce competitive inhibition. Instead, the present results suggest that the inhibition is non-competitive. Thus, it appears that the dyes interact with the CD4 antigen, reducing the number of sites available for binding gp120. Such a mechanism has the potential of being specific for the inhibition of binding of ligands recognizing the CD4 antigen.
In conclusion, the present study identifies a group of dyes which may produce their anti-HIV effects by blocking gp120/CD4 binding. Based on the small sample size, it is not possible to specify the structural requirements for this activity. Given the promising results of this study, a broader survey of dyes along the lines of the present study seems warranted so that the structural requirement for binding inhibition can be determined. This information could yield novel and therapeutically important drugs for the treatment of AIDS.
Materials and Experimental procedures

Preparation of gp 120
Both cell-derived and recombinant gp120 were prepared as previously described (Kozlowski and Watson, 1990) . For preparation of cell-derived gp120, CEM cells at late stage of infection with HIV(LAVBru) (-46% viable), were harvested and resuspended at 108/ml in a buffer containing 2% Triton X100 .and the protease inhibitor PMSF. After 2h at room temperature the supernatant from the solubilized cells was clarified by centrifugation at 18000 rprn for 45 min. The cell lysate was diluted to 0.25% NP40, and the glycoprotein fraction collected on 11 lentil lectin Sepharose 4B column. The column was eluted with a buffer containing 0.5M methyl mannoside and 0.25% Triton X100. The lentil lectin column eluate was run over an anti-gp41 affinity column (antibody 41-1; Schrier and Goldstein, 1987) to remove gp41 and any contaminating gp160. Gp120 was isolated from the flow through fractions by passage over an anti-gp120 affinity column (antibody 110-1; Schrier and Goldstein, 1987) . The column was then washed extensively in buffer without detergent until spectrophotometric determinations of the wash confirmed detergent removal. The gp120 was eluted using a 1 : 100 dilution of triethylamine in saline, pH 11.5. Eluting fractions were immediately neutralized using excess Tris buffer at pH 7.4. Fractions containing gp120 were pooled and dialysed against three changes of phosphate buffered saline (PBS). Protein concentration was estimated by absorption at 205 nm using the procedure of Scopes (1986) . For preparation of recombinant gp120, BCS 40 cells were infected with a recombinant vaccinia virus construct containing the sequence for HIV-1 (V-gp120). The bulk of the gp120 is secreted and can be recovered from the medium by binding to a lentil-lectin column. Detergents were not used in the purification process.
Radialabelling of gp 120
For radiolabelling of both types of gp120, -3.5 p..g of glycoprotein was combined with -300 p.Ci di-iodinated Bolton-Hunter reagent (NEN, 4400Ci rnmol:") for a molar ratio of 3.4:1 (Bolton-Hunter reagent to glycoprotein). Labelling was conducted for 2 h at room temperature in PBS at pH 8.0. A PD10 column (Pharmacia) equilibrated with PBS, 1mg rnr' gelatin, and 0.02% sodium azide was used to remove unincorporated Bolton-Hunter reagent. SDS-PAGE and Western blot analysis has shown that radioligand prepared in this way is relatively pure (Kozlowski and Watson, 1990) . Incubation of the column-purified radioiodinated gp120 e 25 1-gp120) with CEM cells under conditions of binding site excess has demonstrated that at least 40% of the label is present in a form capable of binding (Kozlowski and Watson, 1990) . The labelled ligand was stored at 4°C and used within one week. Binding assays were also performed as previously described (Kozlowski and Watson, 1990) .
Gp120/CD4 binding assay
The CEM cells for the assay were cultured in RPMI1640 (Gibco) and 10% fetal bovine serum (J.R. Scientific). The cells were grown to a density of 1.5 million cells ml-1 in 890cm 2 roller bottles (Falcon), and were supplemented with fresh medium 24 h prior to their use in the assay. The cells were collected by centrifugation (1000 rpm, 10 min, 4°C) and resuspended in ice-cold PBS (Sigma Chemical Co., St Louis, MO, USA) pH 7.4 supplemented with 0.1% bovine serum albumin (BSA; Sigma) and 0.1% D-glucose (Sigma) (PBG). The resuspended CEM cells (2.5 x 10 6 cells in 100 p..1 of PBG) were incubated at room temperature for 30 min in the presence of various concentrations of one of the dyes, 5 p..g mr ' of the anti-CD4a antibody, G17-2, or additional PBG. Prior experiments showed that 1251-gp120 binding increases linearly with cell number between 1.25 x 10 6 and 5 x 10 6 cells per incubation (data not shown). Following this preincubation, a 100p..1 solution of 1251-gp120 (O.4nM for inhibition experiments, 0.0043 nM-3.2 nMfor saturation experiments) was added and the mixture was incubated for 2-3h at 37"C. Since radioligands produced from either source of gp120 (see above) produced comparable results, they were used interchangeably. SDS-PAGE analysis has shown that the ligand is not degraded during the incubation period (Kozlowski and Watson; . The incubation was terminated by collecting the cells by centrifugation (2000 rpm, 30s, 4°C). The cells were washed with fresh ice-cold PBG and repelleted twice. For quantification, the final pellet was collected by filtration using an automatic cell harvester (Tomtec, Oranqe, CT, USA) onto filters pre-soaked in 0.1% BSA. The filters Werewashed twice after the filtration with ice-cold PBS supplemented with 0.1% BSA. Radioactivity trapped by the filters was measured by scintillation counting using a Betaplate counter (LKB) normalized with the appropriate standards. Non-specific binding was taken as that occurring in the incubations in which the G17-2 antibody was present. Specific binding was defined as total binding minus non-specific binding. In some experiments, the initial portion of the saturation curve (0.02nM-1 nM1251-gp120) was repeated with the same concentration of CEM cells, but 10 times the incubation volume. No differences in results were seen when using recombinant gp120 versus cell-derived gp120 for the ligand, so the data were combined. G17-2 was provided by J.
Ledbetter, Oncogen Corp., Seattle, WA (Lasky et a/., 1987) . The dyes were purchased from Aldrich Chemical Company Inc. and used as received.
